Managed Markets

Everyday Health adds payer expert

The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.

CVS changes name

Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."

Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Employers like "skinny" health plans

These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.

Boehringer to cut costs by 15%

Layoffs are reported to be in the offing.

Scotland's NICE dislikes GSK's Anoro

The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.

Britain's NICE sidelines Kadcyla

Britain's NICE sidelines Kadcyla

Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.

Site has doctors bid for business

Medibid users auction up care in exchange for a low price.

Express Scripts drops Zohydro, brings back Advair

The PBM dropped 25 more drugs from its formulary.

Biotech Report: Ultra Man

Biotech Report: Ultra Man

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.